ARTICLE | Management Tracks
Bob Valamehr to succeed CEO Scott Wolchko at Fate
Plus: Amoolya Singh named CTO of Delfi and updates from Torl, OSE and George Clinical
December 3, 2024 12:47 AM UTC
Scott Wolchko will retire on Dec. 31 as president and CEO of Fate Therapeutics Inc. (NASDAQ:FATE), which is developing off-the-shelf cell therapies derived from induced pluripotent stem cells. President of R&D Bob Valamehr, a Fate veteran of nearly 15 years, will succeed Wolchko.
Liquid biopsy company Delfi Diagnostics Inc. hired Amoolya Singh as CTO. Singh was SVP of data science and CSO of Grail Inc. (NASDAQ:GRAL)...